NCT00130689View on ClinicalTrials.gov

Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

43

Participants

Timeline

Start Date

July 31, 2005

Primary Completion Date

September 30, 2010

Study Completion Date

September 30, 2010

Conditions
Esophageal CancerGastric CancerNeoplasm Metastasis
Interventions
DRUG

Cetuximab

Trial Locations (4)

02114

Massachusetts General Hospital, Boston

02115

Beth Israel Deaconess Medical Center, Boston

Dana-Farber Cancer Institute, Boston

Unknown

North Shore Medical Center Cancer Center, Peabody

Sponsors

Collaborators (1)

Bristol-Myers Squibb
All Listed Sponsors
collaborator

Bristol-Myers Squibb

INDUSTRY

collaborator

Massachusetts General Hospital

OTHER

collaborator

Beth Israel Deaconess Medical Center

OTHER

lead

Dana-Farber Cancer Institute

OTHER

NCT00130689 - Use of Cetuximab for Unresectable or Metastatic Esophageal and Gastric Cancer | Biotech Hunter | Biotech Hunter